Loomis, Sayles & Company
CCXI

Loomis, Sayles & Company’s ChemoCentryx, Inc. CCXI Stock Holding History

Loomis, Sayles & Company’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-831,264
Closed -$42.6M – 943
2021
Q1 		$42.6M Buy
831,264
+67,091
+9% +$4.04M 0.06% 177
2020
Q4 		$47.3M Buy
764,173
+286,601
+60% +$16.4M 0.06% 139
2020
Q3 		$26.2M Buy
477,572
+185,453
+63% +$9.98M 0.04% 191
2020
Q2 		$16.8M Buy
+292,119
New +$15.9M 0.03% 249

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Loomis, Sayles & Company's CCXI Position: Q2 2021 in Review

Loomis, Sayles & Company sold out of ChemoCentryx, Inc. (CCXI) in Q2 2021, closing a stake of 831,264 shares — an estimated $42.6M sold.

Loomis, Sayles & Company first reported a position in CCXI in Q2 2020 and held it in 4 quarters. The position peaked at $47.3M in Q4 2020. 146 funds tracked by Wall St. Rank hold CCXI as of Q2 2021.

  • Loomis, Sayles & Company reported no remaining ChemoCentryx, Inc. position as of Q2 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 831,264 ChemoCentryx, Inc. shares in Q2 2021, an estimated $42.6M.
  • Loomis, Sayles & Company first reported a position in ChemoCentryx, Inc. in Q2 2020 and held it in 4 quarters.
  • Loomis, Sayles & Company's ChemoCentryx, Inc. position peaked at $47.3M in Q4 2020.
  • 146 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2021.

Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.